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In February 2006, a patient colonized with a multidrug-
resistant sequence type 56 Acinetobacter baumannii strain 
was admitted to a hospital in Madrid, Spain. This strain 
spread rapidly and caused a large outbreak in the hospital. 
Clinicians should be alert for this strain because its spread 
would have serious health consequences.
T
he increasing resistance of Acinetobacter baumannii 
to antimicrobial drugs, including carbapenems (1–
3), and resistance to desiccation and disinfectants (4) 
contribute to its persistence in hospital environments and 
propensity to cause outbreaks (5,6). In February 2006, a 
patient colonized with a multidrug-resistant A. baumannii 
strain was admitted to the medical–surgical intensive care 
unit (ICU) of a hospital in Madrid, Spain. This strain then 
spread rapidly, persisted for >30 months, and caused a large 
outbreak in the hospital. We report details of this outbreak.
The Study
We conducted a retrospective longitudinal study at 12 
de Octubre University Hospital, Madrid, Spain, of patients 
colonized/infected with A. baumannii during January 
2006–May 2008. We also conducted a cohort study of 
patients with A. baumannii bacteremia during January 
2002–May 2008.
MICs of drugs were conﬁ  rmed by using Etest strips (AB 
Biodisk, Solna, Sweden) according to the manufacturer’s 
criteria. Multidrug-resistant (MDR) phenotypes were 
deﬁ  ned as resistance to 5 classes of drugs: antipseudomonal 
cephalosporins (ceftazidime, cefepime), carbapenems 
(imipenem, meropenem), piperacillin/tazobactam, ﬂ  uoro-
quinolones, and aminoglycosides (gentamicin, tobramycin, 
amikacin). Isolates were classiﬁ   ed on the basis of 
antimicrobial susceptibility patterns: antibiotype 1, MDR 
isolates; antibiotype 2, isolates resistant to carbapenems 
but not MDR; and antibiotype 3, isolates susceptible to 
carbapenems. Colonization was deﬁ  ned as isolation of A. 
baumannii from >1 clinical specimen in the absence of 
clinical symptoms consistent with infection. Bacteremia was 
determined by application of criteria proposed by the Centers 
for Disease Control and Prevention (Atlanta, GA, USA) (7).
Clonal relatedness between clinical isolates was 
determined by using pulsed-ﬁ   eld gel electrophoresis 
(PFGE) and the CHEF DRIII system (Bio-Rad Laboratories, 
Hercules, CA, USA) according to reported techniques 
(8). Migration of DNA fragments was normalized, and 
computer-assisted analysis of PFGE patterns was conducted 
by using Bionumerics software (Applied Maths, Sint-
Martens-Latem, Belgium). Multilocus sequence typing 
(MLST) was performed according to published protocols 
(9). Isolates were assigned to a sequence type according 
to the allelic proﬁ   les database (http://pubmlst.org/
abaumannii/). Univariate analysis was performed by using 
the t test for continuous variables and the χ2 or Fisher exact 
tests for categorical variables. Adjusted odds ratios (ORs) 
were calculated by using logistic regression analysis. Data 
were analyzed by using SPSS software (SPSS Inc., Chicago, 
IL, USA). A p value <0.05 was considered signiﬁ  cant.
During January 2006–May 2008, a total of 377 patients 
were colonized/infected with A. baumannii. Mean age of 
the patients was 57 years and 63.4% were men. Patients 
were hospitalized mostly in ICUs (184, 48.8%), and in 
surgical (100, 26.5%), medical (85, 22.5%), and pediatric 
(8, 2.1%) wards. A total of 76.9% (290/377) of the isolates 
were antibiotype 1, 9.0% (34/377) were antibiotype 2, and 
14.1% (53/377) were antibiotype 3. Temporal distribution 
of cases is shown in Figure 1, panel A. Bacterial isolates of 
antibiotype 1 were assigned to the major clonal type (clone 
AbH12O-A2) by PFGE. Of 290 patients with A. baumannii 
antibiotype 1 isolates (clone AbH12O-A2), 165 patients 
were infected (57%) and 125 (43%) were colonized.
MLST analysis of 3 isolates belonging to clone 
AbH12O-A2 was performed to determine the relationship 
between these isolates and other described strains. The 3 
isolates showed the same allelic proﬁ  le of 7 housekeeping 
genes (allele no. in brackets; gltA [1], gyrB [18], gdhB 
[18], recA [10], cpn60 [14], gpi [29], and rpoD [18]) and 
were identiﬁ  ed as sequence type 56 according to the MLST 
database (http://pubmlst.org/abaumannii/).
A. baumannii clone AbH12O-A2, which showed a 
broad antimicrobial drug-resistance proﬁ  le, resistance to 
carbapenems, and susceptibility only to tigecycline and 
colistin, was present throughout the entire 30-month study 
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and peaked several times until the medical–surgical ICU 
was refurbished in July 2007. The number of new case-
patients with clone AbH12O-A2 then decreased; <3 cases/
month were observed during October 2007–February 2008 
(Figure 1, panel A).
Annual incidence of A. baumannii bacteremia increased 
from 0.03 episodes/100,000 bed days in 2002 to 1.1/100,000 
bed days in 2007 (Figure 1, panel B), which coincided 
with the outbreak peak caused by clone AbH12O-A2. 
Clinical features of patients with A. baumannii bacteremia 
are shown in Table 1. Multivariate analysis of bacteremia 
caused by clone AbH12O-A2 and nonclone AbH12O-A2 
showed that variables independently associated with 
AbH12O-A2 bacteremia were hospitalization in ICUs (OR 
3.48, 95% conﬁ  dence interval [CI] 1.23–9.54), exposure 
to >3 antimicrobial drugs (OR 3.13, 95% CI 1.12–8.76), 
and ventilator-associated pneumonia as the source of 
bacteremia (OR 8.35, 95% CI 1.12–8.76).
Plasmid pMMA2 (GenBank accession no. GQ377752), 
which was isolated from the clone causing the outbreak 
(AbH12O-A2), harbored a blaOXA-24 gene (10) coding 
for carbapenemase OXA-24 (also called OXA-40) as 
described (11). Four additional clones were detected during 
the outbreak (AbH12O-D, AbH12O-CU1, AbH12O-CU2, 
and AbH12O -CU3), which harbored plasmids pMMD, 
pMMCU1, pMMCU2, and pMMCU3, respectively 
(GenBank accession nos. GQ904226, GQ342610, 
GQ476987, and GQ904227). Carbapenem resistance in 
all clones was linked to a plasmid harboring the blaOXA-24 
gene ﬂ  anked by XerC/XerD-like recombination sites (11). 
Comparative analysis among plasmid sequences showed 
different patterns and coding regions. All plasmids, 
including pMMA2, harbored the blaOXA-24 gene as part of 
a DNA module ﬂ  anked by XerC/XerD-like sites, which 
suggested that these sites are involved in mobilization 
of DNA containing the bla  OXA-24 gene by site-speciﬁ  c 
recombination (11).
Two genes with a putative role in virulence were detected 
in plasmids from clones AbH12O-A2 and AbH12O-CU3 
upstream of blaOXA-24: a septicolysin-like gene coding for 
a pore-forming toxin (12), and a TonB-dependent receptor 
gene coding for an outer membrane protein involved in iron 
uptake and virulence (13–15). Insertion sequence 4, which 
provided an additional promoter sequence, was detected 
upstream from the septicolysin gene in plasmid pMMA2; 
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Figure 1. Temporal distribution of patients with Acinetobacter 
baumannii infections, Spain.  A) Patients colonized/infected with 
A. baumannii classiﬁ   ed by antibiotype. Arrows indicate times of 
intensiﬁ  cation of infection control measures. The medical–surgical 
intensive care unit at Octubre University Hospital, Madrid, Spain, 
was refurbished in July 2007. B) Annual incidence of A. baumannii 
bacteremia. ABCA, A. baumannii clone A or AbH12O-A2; ABNCA: 
A. baumannii nonclone A.
Figure 2. Nucleotide sequence of the region between the septicolysin 
and Ton-B dependent receptor genes of Acinetobacter baumannii 
in plasmids pMMA2 and pMMCU3 from clone AbH12O-A2 
(upper panel) and AbH12O-CU3 (lower panel), respectively. 
Integrated insertion sequence 4 (IS4) (red letters) provided a new 
promoter sequence for septicolysin in plasmid pMMA2 from clone 
AbH12O-A2. Upper case letters indicate amino acids. IRL, inverted 
repeated left sequence; IRR, inverted repeated right sequence 
from IS4; Stop, stop (termination) codon.this sequence was absent in plasmid pMMCU3 (Figure 
2). Two nucleotide changes detected in promoter regions 
provided an additional promoter region for the TonB-
dependent receptor gene in plasmid pMMA2.
Real-time PCR (Table 2) was performed to analyze 
expression of septicolysin and TonB-dependent receptor 
genes in clones AbH12O-A2 and AbH12O-CU3. 
Expression of septicolysin in clone AbH12O-A2 was 2.1× 
times higher than that of clone AbH12O-CU3. Conversely, 
the TonB-dependent receptor was also overexpressed in 
clone AbH12O-A2 (1.8× higher than in clone AbH12O-
CU3).
Conclusions
Outbreaks of MDR A. baumannii have been 
demonstrated in many studies (1,2,5). We report a large 
outbreak during 2006–2008 that persisted for >30 months. 
The AbH12O-A2 strain was pathogenic and caused 65 
cases of bacteremia.
Clone AbH12O-A2 had unique characteristics. First, 
it was an MDR (including carbapenems) clone (ST56), 
susceptible only to tigecycline and colistin. Second, it 
harbored a carbapenemase blaOXA-24 gene, ﬂ  anked  by 
XerC/XerD binding sites located on a plasmid, which 
probably spread to other Acinetobacter clones by a Xer 
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Table 1. Clinical characteristic of patients with Acinetobacter baumannii bacteremia, Spain* 
Characteristic
Clone ABCA, 
n = 65 
Clone ABNCA, 
n = 29  p value  OR (95% CI) 
Age, y  57.5 ± 14.2  58.7 ± 19.6  0.730  NA
Male sex  50 (76.9)  21 (72.4)  0.639  1.27 (0.47–3.45) 
Concurrent conditions 
  Immunosuppression  12 (18.5)  6 (20.7)  0.800  0.87 (0.29–2.60) 
  Solid tumor  16 (24.6)  6 (20.7)  0.678  1.25 (0.43–3.62) 
  Hematologic malignancy  1 (1.5)  1 (3.4)  0.553  0.44 (0.03–7.25) 
  Diabetes mellitus  9 (13.8)  9 (31.0)  0.050  0.36 (0.12–1.03) 
  Liver cirrhosis  11 (16.9)  3 (10.3)  0.408  1.76 (0.45–6.88) 
  Heart failure  4 (6.2)  3 (10.3)  0.475  0.57 (0.12–2.72) 
  Chronic obstructive pulmonary disease  7 (10.8)  3 (10.3)  0.951  1.05 (0.25–4.37) 
  Liver transplant  15 (23.1)  7 (24.1)  0.911  0.94 (0.34–2.64) 
Duration of hospitalization before A. baumannii bacteremia, d  34.8 ± 36.1  23.9 ± 27.5  0.150  NA
Hospital location 
  Intensive care unit  41 (63.1)  9 (31.0)  0.004  3.80 (1.50–9.66) 
  Medical ward  6 (9.2)  12 (41.4)  0.001  0.14 (0.05–0.44) 
  Surgical ward  18 (27.7)  8 (27.6)  0.992  1.00 (0.38–2.68) 
Source of bacteremia 
  Catheter-related infection  25 (38.5)  9 (31.0)  0.489  1.39 (0.54–3.52) 
  Pneumonia associated with mechanical ventilation  18 (27.7)  1 (3.4)  0.006  10.72 (1.36–84.8) 
  None (primary bacteremia)  12 (18.5)  14 (48.3)  0.003  0.24 (0.09–0.63) 
  Intraabdominal infection  7 (10.8)  2 (6.9)  0.716  1.62 (0.32–8.37) 
  Urinary tract infection  3 (4.6)  2 (6.9)  0.642  0.65 (0.10–4.13) 
  Other  0 1 (3.4)  0.309  3.32 (2.43–4.52) 
Carbapenem resistance  65 (100.0)  7 (24.1)  0.001  0.09 (0.50–0.20) 
Prior colonization with A. baumannii 43/62 (69.4)  1/17 (5.9)  0.001  36.21(4.47–293.1) 
Antimicrobial drugs used 
  Cephalosporin  7/62 (11.3)  3/29 (10.3)  0.893  1.10 (0.26–4.61) 
  Piperacillin/tazobactam  21/62 (33.9)  4/29 (13.8)  0.046  3.20 (0.98–10.41) 
  Fluorquinolone  24/62 (38.7)  9/29 (31.0)  0.478  1.40 (0.54–3.59) 
  Glycopeptide  44/62 (71.0)  12/29 (41.4)  0.007  3.46 (1.38–8.69) 
  Aminoglycoside  17/62 (27.4)  8/29 (27.6)  0.987  0.99 (0.37–2.66) 
  Carbapenem  41/62 (66.1)  11/29 (37.9)  0.011  3.20 (1.28–7.99) 
 > 3 drugs  36/62 (58.1)  8/29 (27.6)  0.007  3.63 (1.40–9.47) 
Invasive procedure or device 
  Central venous catheter†  51/64 (79.7)  15/29 (51.7)  0.006  3.66 (1.42–9.46) 
  Surgical procedure‡  33/64 (51.6)  11/29 (37.9)  0.223  1.74 (0.71–4.27) 
  Mechanical ventilation†  49/64 (76.6)  14/29 (48.3)  0.007  3.50 (1.38–8.87) 
Duration of hospitalization after A. baumannii bacteremia, d  46.6 ± 72.9  20.5 ± 21.2  0.050  NA
Died during hospitalization  35 (53.8)  9 (31.0)  0.041  2.59 (1.03–6.54) 
*Values are mean ± SD or no. (%) except as indicated. Clone ABCA, A. baumannii clone A (AbH12O-A2); ABNCA, A. baumannii nonclone A; 
OR, odds ratio; CI, confidence interval; NA, not applicable. 
†Week before bacteremia. 
‡Month before bacteremia. MDR A. baumannii, Spain
recombination system (11). Third, this clone overexpressed 
2 putative virulence factors, septicolysin and TonB-
dependent receptor. 
The septicolysin gene showed 2× overexpression 
caused by insertion of IS4, which provided an additional 
promoter. Although the exact role of septicolysin is 
unknown, it has been designated a cholesterol-dependent 
cytolysin, which has been reported to be produced by 
pathogenic bacteria such as Clostridium perfringens, 
Bacillus anthracis, and Streptococcus pneumoniae to aid 
invasion of tissues or cells (12).
The protein produced by the TonB-dependent receptor 
gene has been associated with virulence and iron uptake 
in  A. baumannii ( 13) and may be involved in survival 
of bacteria in the lungs and blood. This characteristic 
may explain the large rate of bacteremia caused by clone 
AbH12O-A2. Thus, clinicians should be alert for the MDR 
ST56 A. baumannii clone because its spread would have 
serious health consequences.
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Table 2. Oligonucleotides used in real-time reverse transcription PCRs for Acinetobacter baumannii, Spain* 
Primer Gene  Sequence,  5ƍ o 3ƍ 
TonB-Forw TonB-dependent  receptor  GGACTGGTGATAAAGCACTAT 
TonB-Rev TonB-dependent  receptor  GCCGCATAGAGTTATCACATC 
Septicolysin-Forw Septicolysin  CACCATCTTGTACCAATACATTT 
Septicolysin-Rev Septicolysin  GAAATTAGCAGAAGCTCTCTTAC 
rpoB-Forw  RNA polymerase subunit B  CAGCCGCGAYCAGGTTGACTACA 
rpoB-Rev  RNA polymerase subunit B  GACGCACCGCAGGATACCACCTG 
gyrB-Forw  DNA gyrase subunit B  AAGTGAGGTAAAACCAGCGGTA 
gyrB-Rev  DNA gyrase subunit B  AATCTTGCCTGCAATTGATTTT 
*Forw, forward; rev, reverse. 